Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double‐blind, placebo‐controlled trial
Authors' conclusion
For adults with obesity, diacerein led to a clinically meaningful weight loss and provided multiple metabolic benefits with acceptable safety. These results support that diacerein is a promising candidate medicine to be developed for obesity management.
Study context
- Population
- Adults with obesity
- Participants
- 42 adults
- Comparison
- Diacerein vs placebo, each with lifestyle modification
Methodological detailsdouble-blind, placebo-controlled
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Weight loss % from baseline · 14 weeks
Diacerein
−6.56%
interval −8.71%–-4.41%
Placebo
−0.59%
interval −2.74%–1.56%
Further findings
Body composition, metabolic variables and fatty liver indicators
- Significant improvements with diacerein vs placebo
Serum visfatin · 14 weeks
- Significant reduction with diacerein vs placebo
Mediation of weight loss
- Reductions in total body fat mass and visceral fat area mediated diacerein-induced weight loss
Safety
- No significant differences between groups in number of adverse events and safety variables
Original publication
Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double‐blind, placebo‐controlled trial. Diabetes Obes Metab. Published 27 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →